Richardson Electronics (RELL) Q3 2025 earnings summary

Executive summary

• Q3 FY25 net sales rose 2.7% year-over-year to $53.8M; nine-month sales up 5.3% to $157.0M, with strong semiconductor wafer fab (up 139%) and Canvys (up 39.5%) performance.

• Positive operating cash flow for the fourth consecutive quarter; ended Q3 with $36.7M in cash and no debt.

• Completed sale of majority of Healthcare assets to DirectMed Imaging for $8.2M, incurring a $4.9M loss and entering a 10-year supply agreement.

• Non-GAAP operating profit rose to $2.2M from $1M year-over-year, excluding the Healthcare charge.

• Board declared a $0.06 per share quarterly cash dividend.

Financial highlights

• Q3 consolidated gross margin improved to 31.0% from 29.5% year-over-year, with GES and PMT margin gains.

• Q3 net loss was $2.1M; non-GAAP net income was $1.6M, up from $0.8M last year.

• Adjusted EBITDA for Q3 was $2.8M, up from $2.1M year-over-year.

• Operating cash flow for nine months was $10.5M, up from a $0.7M outflow in the prior year period.

• Total backlog at Q3 FY25 end was $134.1M, up over 120% since FY2019.

Outlook and guidance

• Expect continued growth in GES and PMT in Q4 and FY26, supported by strong backlog and new product introductions.

• Anticipate further investments in business development and engineering to accelerate product launches and global expansion.

• Management expects existing liquidity and cash flow to meet capital and working capital needs for the next twelve months.

• Near-term volatility expected due to global trade and U.S. economic policies.

• Healthcare segment will be consolidated into PMT in future periods.